Stiripentol for focal refractory epilepsy

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Brigo, Francesco ^a   Storti, Monica ^a  

^a FRANZ TAPPEINER HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

STIRIPENTOL; 1,3 DIOXOLANE DERIVATIVE; ANTICONVULSIVE AGENT;

ADD ON THERAPY; CLINICAL OUTCOME; DRUG EFFECT; DRUG EFFICACY; DRUG RESISTANT EPILEPSY; EXPERIMENTAL DESIGN; EXTERNAL VALIDITY; GASTROINTESTINAL DISEASE; HUMAN; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; FOCAL EPILEPSY;

ANTICONVULSANTS; DIOXOLANES; EPILEPSIES, PARTIAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903784702     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009887.pub2     Document Type: Review

References (24)

1. Chiron C, Tonnelier S, Rey E, Brunet ML, Tran A, d'Athis P, et al. Stiripentol in childhood partial epilepsy: randomized placebo-controlled trial with enrichment and withdrawal design. Journal of Child Neurology 2006;21(6):496-502.
2. Chiron C, Tran A, Rey E, d'Athis P, Vincent J, Tonnelier S, et al. Stiripentol in childhood partial epilepsy: A placebo-controlled trial. Epilepsia 2000;41 Suppl 7:191.
3. Loiseau P, Strube E, Tor J, Levy RH, Dodrill C. Neurophysiological and therapeutic evaluation of stiripentol in epilepsy. Preliminary results. Revue Neurologique 1988;144(3):165-72.
4. Loiseau P, Levy RJ, Houin G, Rascol O, Dordain G. Randomized double-blind, parallel, multicenter trial of stiripentol added to carbamazepine in the treatment of carbamazepine-resistant epilepsies. An interim analysis. Epilepsia 1990;31(5):618-9.
5. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d'Athis P, et al. stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999;40(11):1618-26.
6. Rascol O, Squalli A, Montastruc JL, Garat A, Houin G, Lachau S, et al. A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. Clinical Neuropharmacology 1989;12(2):119-23.
7. Berg AT, Kelly MM. Defining intractability: Comparisons among published definitions. Epilepsia 2006;47(2):431-6.
8. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51(4):676-85.
9. Brigo F, Storti M. Stiripentol for focal refractory epilepsy. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009887]
10. Brigo F, Storti M, Del Felice A. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010483]
11. Chiron C. Stiripentol. Expert Opinion on Investigational Drugs 2005;14:905-11.
12. Chiron C. Stiripentol. Neurotherapeutics 2007;4:123.
13. Cockerell OC, Johnson L, Sander JWAS, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346:104-44.
14. Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 2009;56:190-7.
15. French JA. Refractory epilepsy: one size does not fit all. Epilepsy Currents 2006;6:177-80.
16. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metabolism and Disposition 2006;34:608-11.
17. Granata T, Marchi N, Carlton E, Ghosh C, Gonzalez-Martinez J, Alexopoulos AV, et al. Management of the patient with medically refractory epilepsy. Expert Review of Neurotherapeutics 2009;9:1791-802.
18. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
19. International League Against Epilepsy. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
20. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77.
21. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org/.
22. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 2006;47:704-16.
23. Strauss S, Richardson W, Glasziou P, Haynes R. Evidence-Based Medicine: How to Practice and Teach EBM. 3rd Edition. Edinburgh, United Kingdom: Churchill Livingstone, 2005.
24. Brigo F, Storti M. Stiripentol for focal refractory epilepsy. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009887]